Home › Ovarian Cancer › Arizona
Ovarian Cancer clinical trials in Arizona
26 studies for Ovarian Cancer are looking for participants at sites in Arizona.
Cities in Arizona
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- CTCA at Western Regional Medical Center, Goodyear
- Kingman Regional Medical Center, Kingman
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0143 - HonorHealth, Phoenix
- Site 0102 - University of Arizona Cancer Center, Tucson
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Phoenix
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722DESTINY-PANTUMOUR04
- Research Site, Bullhead City
- Research Site, Casa Grande
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- HonorHealth, Phoenix
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Arizona Cancer Center, Tucson
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- University of Arizona Cancer Center, Tucson
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0107, Phoenix
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Mayo Clinic (Arizona), Scottsdale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068AOH1996 for the Treatment of Refractory Solid Tumors
- Honor Health Research and Innovation Institute, Scottsdale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT05227326Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #108, Goodyear
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06545942Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- Mayo Clinic Arizona, Phoenix
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 14, 2026 · NCT05804370A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Banner Health, Gilbert
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Phoenix
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
- Mayo Clinic in Arizona, Scottsdale
RecruitingPhase 1
Ages 18 and older · Women · Updated Mar 16, 2026 · NCT06483048A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- HonorHealth Research Institute, Scottsdale
- The University of Arizona Cancer Center, Tucson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Mayo Clinic Hospital, Phoenix
- SCRI - Arizona Oncology Associates, PC-HOPE, Tucson
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.